<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 09 Feb 2021 07:25:40 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>百奥泰终止HER2 ADC临床，已投入研发费用2.26亿元</title><link>https://mp.weixin.qq.com/s/T0SWF17erNP83hrfv3jjCA</link><description></description><content:encoded><![CDATA[百奥泰终止HER2 ADC临床，已投入研发费用2.26亿元]]></content:encoded><pubDate>Tue, 09 Feb 2021 00:06:00 +0800</pubDate></item><item><title>康希诺新冠疫苗有效率65.7%</title><link>https://mp.weixin.qq.com/s/H5WgdUEHX-ErBpLTB80oLQ</link><description></description><content:encoded><![CDATA[康希诺新冠疫苗有效率65.7%]]></content:encoded><pubDate>Tue, 09 Feb 2021 00:06:00 +0800</pubDate></item><item><title>百奥泰HER2 ADC三期临床未达到优效终点</title><link>https://mp.weixin.qq.com/s/j00Rz4veWlk3Lo5pda_9Fg</link><description></description><content:encoded><![CDATA[百奥泰HER2 ADC三期临床未达到优效终点]]></content:encoded><pubDate>Mon, 08 Feb 2021 17:21:26 +0800</pubDate></item><item><title>尚健生物申报PD-L1/CD47双抗</title><link>https://mp.weixin.qq.com/s/cF6jEtAtf6vOv6sFY04Zdw</link><description></description><content:encoded><![CDATA[尚健生物申报PD-L1/CD47双抗]]></content:encoded><pubDate>Mon, 08 Feb 2021 17:21:26 +0800</pubDate></item><item><title>多肽药物研发趋势</title><link>https://mp.weixin.qq.com/s/CxBBXubv5QwRJkftNKwOIw</link><description></description><content:encoded><![CDATA[多肽药物研发趋势]]></content:encoded><pubDate>Sun, 07 Feb 2021 15:17:35 +0800</pubDate></item><item><title>2020年全球畅销药TOP20</title><link>https://mp.weixin.qq.com/s/gFmJ71CV80dpMeJkHv-1qw</link><description></description><content:encoded><![CDATA[2020年全球畅销药TOP20]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>第4款CAR-T疗法：Liso-cel终获FDA批准</title><link>https://mp.weixin.qq.com/s/tjO9AHtzQQz8QuYpZPhTvw</link><description></description><content:encoded><![CDATA[第4款CAR-T疗法：Liso-cel终获FDA批准]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>岸迈生物申报PD-1/LAG-3双抗：EMB-02</title><link>https://mp.weixin.qq.com/s/MMhpsN93Mrw0E_TNtAKVJw</link><description></description><content:encoded><![CDATA[岸迈生物申报PD-1/LAG-3双抗：EMB-02]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>瑞德西韦销售额28亿美元，支撑吉利德业绩增长10%</title><link>https://mp.weixin.qq.com/s/gsifGUY3-EIECla4SacuwA</link><description></description><content:encoded><![CDATA[瑞德西韦销售额28亿美元，支撑吉利德业绩增长10%]]></content:encoded><pubDate>Fri, 05 Feb 2021 13:58:26 +0800</pubDate></item><item><title>复宏汉霖申报LAG-3抗体：HLX26</title><link>https://mp.weixin.qq.com/s/jUuKE6vgoJcrMd4aek5TcA</link><description></description><content:encoded><![CDATA[复宏汉霖申报LAG-3抗体：HLX26]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:14:53 +0800</pubDate></item><item><title>爱思迈申报HER2/CD3双抗：国内第2家</title><link>https://mp.weixin.qq.com/s/fnLTfDJJqz1GzEkmCgbM5w</link><description></description><content:encoded><![CDATA[爱思迈申报HER2/CD3双抗：国内第2家]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:14:53 +0800</pubDate></item><item><title>石药集团申报IL-23抗体：国内第2家</title><link>https://mp.weixin.qq.com/s/bIfC6jViXLqrC2RygF2I1A</link><description></description><content:encoded><![CDATA[石药集团申报IL-23抗体：国内第2家]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:14:53 +0800</pubDate></item><item><title>HanAll FcRn抗体因血脂升高副作用停止TED、WAHA临床，和铂医药未进行相关适应症临床，亦未发现血脂副作用</title><link>https://mp.weixin.qq.com/s/7zuiM2M3IUMs_u8VJKkKsQ</link><description></description><content:encoded><![CDATA[HanAll FcRn抗体因血脂升高副作用停止TED、WAHA临床，和铂医药未进行相关适应症临床，亦未发现血脂副作用]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>安进DLL3-CD3双抗在实体瘤中取得重大突破</title><link>https://mp.weixin.qq.com/s/ndWhDjCLt8WjR9iJGrESRQ</link><description></description><content:encoded><![CDATA[安进DLL3-CD3双抗在实体瘤中取得重大突破]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>诺诚健华增发筹资30.45亿港元，高瓴资本认购26.7亿</title><link>https://mp.weixin.qq.com/s/z8B10CAFZxAB0kSjmFLIdQ</link><description></description><content:encoded><![CDATA[诺诚健华增发筹资30.45亿港元，高瓴资本认购26.7亿]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>地平线30亿美元收购Viela，豪森拥有其CD19抗体中国权益</title><link>https://mp.weixin.qq.com/s/l95fuqgTq2Fhm0reCuVZoQ</link><description></description><content:encoded><![CDATA[地平线30亿美元收购Viela，豪森拥有其CD19抗体中国权益]]></content:encoded><pubDate>Tue, 02 Feb 2021 09:31:51 +0800</pubDate></item><item><title>百亿剂新冠疫苗</title><link>https://mp.weixin.qq.com/s/Ida2cfICmSjuHWujtneO-w</link><description></description><content:encoded><![CDATA[百亿剂新冠疫苗]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:47:06 +0800</pubDate></item><item><title>胰岛素百年传奇</title><link>https://mp.weixin.qq.com/s/dD-fngfSSoFAB2hPsFtuGA</link><description></description><content:encoded><![CDATA[胰岛素百年传奇]]></content:encoded><pubDate>Sun, 31 Jan 2021 14:55:26 +0800</pubDate></item></channel></rss>